ESMO GI 2024 | Minimizing immunotherapy-induced toxicity in patients with GI tumors
Kristen Ciombor
• 28 Jun 2024
Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, comments on managing immunotherapy- induced toxicity in patients. Whilst immunotherapy related toxicity is low in patient populations, ongoing and future research may be helpful in identifying potential risks and optimizing safety profiles for broader use. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
